Functional and Immunohistochemical Characterization of CB1 and CB2 Receptors in Rat Bladder

Urology ◽  
2008 ◽  
Vol 72 (5) ◽  
pp. 1174-1178 ◽  
Author(s):  
Matthew H. Hayn ◽  
Inmaculada Ballesteros ◽  
Fernando de Miguel ◽  
Christian H. Coyle ◽  
Shachi Tyagi ◽  
...  
Keyword(s):  
Rat Bladder ◽  
Cb2 Receptors ◽  
Cb1 And Cb2 Receptors

scholarly journals Functional characterization of the novel cannabinoid receptor GPR55 and its modulation by CB1 and CB2 receptors

2008 ◽  
Vol 8 (Suppl 1) ◽  
pp. A23
Author(s):  
Nariman Balenga ◽  
Julia Kargl ◽  
Christopher M Henstridge ◽  
Andrew J Irving ◽  
Maria Waldhoer
Keyword(s):  
Cannabinoid Receptor ◽  
Functional Characterization ◽  
The Novel ◽  
Cb2 Receptors ◽  
Cb1 And Cb2 Receptors

Characterization of the pharmacology of imidazolidinedione derivatives at cannabinoid CB1 and CB2 receptors

2004 ◽  
Vol 495 (1) ◽  
pp. 43-53 ◽  
Author(s):  
Sophie J Govaerts ◽  
Giulio G Muccioli ◽  
Emmanuel Hermans ◽  
Didier M Lambert
Keyword(s):  
Cb2 Receptors ◽  
Cb1 And Cb2 Receptors

MORPHOLOGICAL AND FUNCTIONAL CHARACTERIZATION OF CB1 AND CB2 RECEPTORS IN RAT, MONKEY AND HUMAN URINARY BLADDER

2008 ◽  
Vol 179 (4S) ◽  
pp. 351-351 ◽  
Author(s):  
Christian Gratzke ◽  
George J Christ ◽  
Tomi Streng ◽  
Anthony Park ◽  
Christian G Stief ◽  
...  
Keyword(s):  
Urinary Bladder ◽  
Functional Characterization ◽  
Human Urinary Bladder ◽  
Cb2 Receptors ◽  
Cb1 And Cb2 Receptors

Pharmacological and molecular characterization of a dorsal root ganglion cell line expressing cannabinoid CB1 and CB2 receptors

2011 ◽  
Vol 659 (2-3) ◽  
pp. 161-168 ◽  
Author(s):  
Yihong Fan ◽  
Bradley A. Hooker ◽  
Tiffany Runyan Garrison ◽  
Odile F. El-Kouhen ◽  
Kenneth B. Idler ◽  
...  
Keyword(s):  
Dorsal Root Ganglion ◽  
Ganglion Cell ◽  
Cell Line ◽  
Molecular Characterization ◽  
Dorsal Root ◽  
Dorsal Root Ganglion Cell ◽  
Cb2 Receptors ◽  
Cb1 And Cb2 Receptors

The role of the peripheral cannabinoid system in the pathogenesis of detrusor overactivity evoked by increased intravesical osmolarity in rats

2015 ◽  
Vol 93 (8) ◽  
pp. 721-726 ◽  
Author(s):  
Kajetan Juszczak ◽  
Piotr Maciukiewicz
Keyword(s):  
Urinary Bladder ◽  
Detrusor Overactivity ◽  
Cannabinoid Receptors ◽  
Bladder Capacity ◽  
Pressure Profile ◽  
Intravesical Instillation ◽  
Motility Index ◽  
Urinary Bladder Dysfunction ◽  
Cb2 Receptors ◽  
Cb1 And Cb2 Receptors

The cannabinoid receptors CB1 and CB2 are localized in the urinary bladder and play a role in the regulation of its function. We investigated the pathomechanisms through which hyperosmolarity induces detrusor overactivity (DO). We compared urinary bladder activity in response to blockade of CB1 and CB2 receptors using AM281 and AM630, respectively, in normal rats and after hyperosmolar stimulation. Experiments were performed on 44 rats. DO was induced by intravesical instillation of hyperosmolar saline. Surgical procedures and cystometry were performed under urethane anaesthesia. The measurements represent the average of 5 bladder micturition cycles. We analysed basal, threshold, and micturition voiding pressure; intercontraction interval; compliance; functional bladder capacity; motility index; and detrusor overactivity index. The blockage of CB1 and CB2 receptors diminished the severity of hyperosmolar-induced DO. In comparison with naïve animals the increased frequency of voiding with no significant effect on intravesical voiding pressure profile was observed as a result of the blockage of CB1 and CB2 receptors. These results demonstrate that hyperosmolar-induced DO is mediated by CB1 and CB2 receptors. Therefore, the cannabinoid pathway could potentially be a target for the treatment of urinary bladder dysfunction.

Enhanced Humoral Immunity in Mice Lacking CB1 and CB2 Receptors (Cnr1 −/− /Cnr2 −/− Mice) is not Due to Increased Splenic Noradrenergic Neuronal Activity

2014 ◽  
Vol 9 (4) ◽  
pp. 544-557 ◽  
Author(s):  
Tyrell Simkins ◽  
Robert B. Crawford ◽  
John L. Goudreau ◽  
Keith J. Lookingland ◽  
Barbara L. F. Kaplan
Keyword(s):  
Neuronal Activity ◽  
Humoral Immunity ◽  
Cb2 Receptors ◽  
Cb1 And Cb2 Receptors

scholarly journals Minor Cannabinoids: Biosynthesis, Molecular Pharmacology and Potential Therapeutic Uses

2021 ◽  
Vol 12 ◽  
Author(s):  
Kenneth B. Walsh ◽  
Amanda E. McKinney ◽  
Andrea E. Holmes
Keyword(s):  
Transient Receptor Potential ◽  
Cannabis Sativa ◽  
Trp Channels ◽  
Current Knowledge ◽  
Synergistic Activity ◽  
Molecular Pharmacology ◽  
Isolation And Characterization ◽  
Therapeutic Uses ◽  
Cb2 Receptors ◽  
Cb1 And Cb2 Receptors

The medicinal use of Cannabis sativa L. can be traced back thousands of years to ancient China and Egypt. While marijuana has recently shown promise in managing chronic pain and nausea, scientific investigation of cannabis has been restricted due its classification as a schedule 1 controlled substance. A major breakthrough in understanding the pharmacology of cannabis came with the isolation and characterization of the phytocannabinoids trans-Δ9-tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD). This was followed by the cloning of the cannabinoid CB1 and CB2 receptors in the 1990s and the subsequent discovery of the endocannabinoid system. In addition to the major phytocannabinoids, Δ9-THC and CBD, cannabis produces over 120 other cannabinoids that are referred to as minor and/or rare cannabinoids. These cannabinoids are produced in smaller amounts in the plant and are derived along with Δ9-THC and CBD from the parent cannabinoid cannabigerolic acid (CBGA). While our current knowledge of minor cannabinoid pharmacology is incomplete, studies demonstrate that they act as agonists and antagonists at multiple targets including CB1 and CB2 receptors, transient receptor potential (TRP) channels, peroxisome proliferator-activated receptors (PPARs), serotonin 5-HT1a receptors and others. The resulting activation of multiple cell signaling pathways, combined with their putative synergistic activity, provides a mechanistic basis for their therapeutic actions. Initial clinical reports suggest that these cannabinoids may have potential benefits in the treatment of neuropathic pain, neurodegenerative diseases, epilepsy, cancer and skin disorders. This review focuses on the molecular pharmacology of the minor cannabinoids and highlights some important therapeutic uses of the compounds.

Virtual screening using Docking and Molecular Dynamics of cannabinoid analogues against CB1 and CB2 receptors

2021 ◽  
pp. 107590
Author(s):  
Antistio Avíz-Amador ◽  
Neyder Contreras-Puentes ◽  
Jairo Mercado-Camargo
Keyword(s):  
Molecular Dynamics ◽  
Virtual Screening ◽  
Cb2 Receptors ◽  
Cb1 And Cb2 Receptors

scholarly journals Cross-regulation of cannabinoid CB1 and CB2 receptors governs hepatic steatosis

2010 ◽  
Vol 30 (10) ◽  
pp. 1397-1399 ◽  
Author(s):  
Ying-Ying Yang ◽  
Han-Chieh Lin
Keyword(s):  
Hepatic Steatosis ◽  
Cb2 Receptors ◽  
Cb1 And Cb2 Receptors

scholarly journals Evidence for inverse agonism of SR141716A at human recombinant cannabinoid CB1 and CB2 receptors

1998 ◽  
Vol 124 (4) ◽  
pp. 619-622 ◽  
Author(s):  
S J MacLennan ◽  
P H Reynen ◽  
J Kwan ◽  
D W Bonhaus
Keyword(s):  
Inverse Agonism ◽  
Cb2 Receptors ◽  
Cb1 And Cb2 Receptors
Sign in / Sign up

Export Citation Format

Share Document